136 related articles for article (PubMed ID: 32675128)
1. Immunotherapy in pancreatic cancer and the importance of tumour testing.
Ngo P; Shanshal M; Rojan A
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32675128
[TBL] [Abstract][Full Text] [Related]
2. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report.
Chen M; Yang S; Fan L; Wu L; Chen R; Chang J; Hu J
Pancreas; 2019 Oct; 48(9):1232-1236. PubMed ID: 31609933
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale.
Wang Y; Cuggia A; Pacis A; Boileau JC; Marcus VA; Gao ZH; Chong G; Foulkes WD; Zogopoulos G
J Natl Compr Canc Netw; 2021 Aug; 19(8):883-887. PubMed ID: 34416708
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of metastatic pancreatic cancer].
Heinemann V; Boeck S; Westphalen CB
Inn Med (Heidelb); 2022 Aug; 63(8):851-862. PubMed ID: 35925070
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
7. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
8. Assessment of mismatch repair deficiency in ovarian cancer.
Crosbie EJ; Ryan NAJ; McVey RJ; Lalloo F; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; Wallace AJ; McMahon RF; Evans DG
J Med Genet; 2021 Oct; 58(10):687-691. PubMed ID: 32917768
[TBL] [Abstract][Full Text] [Related]
9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
10. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
11. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
Kravochuck SE; Church JM
ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
[TBL] [Abstract][Full Text] [Related]
13. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
14. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.
Cloyd JM; Chun YS; Ikoma N; Vauthey JN; Aloia TA; Cuddy A; Rodriguez-Bigas MA; Nancy You Y
J Gastrointest Cancer; 2018 Mar; 49(1):93-96. PubMed ID: 29238914
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
19. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.
Karamurzin Y; Zeng Z; Stadler ZK; Zhang L; Ouansafi I; Al-Ahmadie HA; Sempoux C; Saltz LB; Soslow RA; O'Reilly EM; Paty PB; Coit DG; Shia J; Klimstra DS
Hum Pathol; 2012 Oct; 43(10):1677-87. PubMed ID: 22516243
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.
Flanagan MR; Jayaraj A; Xiong W; Yeh MM; Raskind WH; Pillarisetty VG
World J Gastroenterol; 2015 Mar; 21(9):2820-5. PubMed ID: 25759555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
